Targeted Radiopharmaceuticals Target Selection and Drug Design Summit Revere Hotel Boston Common, Boston

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With strong clinical efficacy from blockbuster drugs Pluvicto and Lutathera, radiopharmaceutical leaders are looking for the next application of this highly efficacious and potent modality!